Get the Stockscreener App
7.67
0.52%
+0.04
After Hours:
7.67
Avid Bioservices Inc stock is currently priced at $7.67, with a 24-hour trading volume of 1.49M.
It has seen a +0.52% increased in the last 24 hours and a +19.47% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $7.57 pivot point. If it approaches the $7.89 resistance level, significant changes may occur.
Previous Close:
$7.63
Open:
$7.61
24h Volume:
1.49M
Market Cap:
$486.89M
Revenue:
$136.74M
Net Income/Loss:
$-17.68M
P/E Ratio:
-170.82
EPS:
-0.0449
Net Cash Flow:
$-38.50M
1W Performance:
+12.30%
1M Performance:
+19.47%
6M Performance:
+31.11%
1Y Performance:
-56.81%
1D Range:
$7.465
$7.85
52W Range:
$4.0705
$18.86
Avid Bioservices Inc Stock (CDMO) Company Profile
Name
Avid Bioservices Inc
Sector
Industry
Phone
714-508-6100
Address
2642 Michelle Drive, Suite 200, Tustin, CA
Avid Bioservices Inc Stock (CDMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-23 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-08-21 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-17-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-10-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Oct-17-19 | Initiated | Stephens | Overweight |
| Oct-16-19 | Initiated | Craig Hallum | Buy |
| Jun-28-19 | Upgrade | Janney | Neutral → Buy |
| May-09-19 | Downgrade | Janney | Buy → Neutral |
View All
Avid Bioservices Inc Stock (CDMO) Latest News
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
GlobeNewswire Inc.
Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q
GlobeNewswire Inc.
S&P 500 Gains 1%; Kroger Earnings Top Views
Benzinga
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Dow Gains 100 Points; Victoria's Secret Shares Plunge
Benzinga
Nasdaq Rises 100 Points; BJ's Wholesale Posts Weak Sales
Benzinga
Avid Bioservices Inc Stock (CDMO) Financials Data
Avid Bioservices Inc (CDMO) Revenue 2024
CDMO reported a revenue (TTM) of $136.74 million for the quarter ending January 31, 2024, a -2.81% decline year-over-year.
Avid Bioservices Inc (CDMO) Net Income 2024
CDMO net income (TTM) was -$17.68 million for the quarter ending January 31, 2024, a -115.22% decrease year-over-year.
Avid Bioservices Inc (CDMO) Cash Flow 2024
CDMO recorded a free cash flow (TTM) of -$38.49 million for the quarter ending January 31, 2024, a +58.34% increase year-over-year.
Avid Bioservices Inc (CDMO) Earnings per Share 2024
CDMO earnings per share (TTM) was -$0.2749 for the quarter ending January 31, 2024, a -116.60% decline year-over-year.
About Avid Bioservices Inc
Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
3.18%
Cap:
|
Volume (24h):